Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

October 20, 2022

Study Completion Date

November 10, 2022

Conditions

Flank Mass

Interventions

DRUG

RZL-012

small synthetic molecule for submental fat reduction

DRUG

Placebo

Trial Locations (1)

Luxurgery, New York

All Listed Sponsors

lead

Raziel Therapeutics Ltd.

INDUSTRY

NCT05445557 - Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks | Biotech Hunter | Biotech Hunter